Cerapedics’ spinal bone graft earns approval for ACDF

Cerapedics earned FDA approval to expand the use of its spinal fusion biologic, i-Factor P-15, according to a Sept. 24 news release.

Advertisement

Indications for the peptide enhanced bone graft now include single-level anterior cervical discectomy fusion with an allograft bone ring. It can also be used in conjunction with a PEEK titanium alloy or fusion device that has been cleared by the FDA for cervical spine use.

The i-Factor bone graft has been used in the U.S. since 2015, Cerapedic CEO Valeska Schroeder said in the release. It is reportedly the only product of its kind that used a P-15 osteogenic cell binding peptide, and studies show it is as safe as a local autograft in single-level ACDF.

Advertisement

Next Up in Biologics

  • Healthcare solutions provider Summit Products Group, based in Dallas, has launched a strategic partnership with regenerative medicine developer NovaBone Products. …

  • From product launches and milestones, here are five updates in orthobiologics since March 28. 1. Lenoss Medical’s OsteoPearl procedure reached…

Advertisement

Comments are closed.